Halaven

Eribulin mesylate

Locally advanced or metastatic breast cancer who have progressed after at least 1 chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline & a taxane in either the adjuvant or metastatic setting unless patients are not suitable in these treatments. Unresectable liposarcoma in adult patients who have received prior anthracycline-containing therapy (unless unsuitable) for advanced or metastatic disease.

IV 1.4 mg/m² over 2-5 min on Days 1 & 8 of every 21-day cycle. Patients w/ mild hepatic impairment (Child-Pugh A) 1.1 mg/m² over 2-5 min on Days 1 & 8 of 21-day cycle. Patients w/ moderate hepatic impairment (Child-Pugh B) 0.7 mg/m² over 2-5 min on Days 1 & 8 of 21-day cycle.

Hypersensitivity. Lactation.

Monitor CBC prior to each dose. Patients w/ febrile neutropenia, severe neutropenia or thrombocytopenia; ALT or AST >3x ULN. Closely monitor for signs of peripheral motor & sensory neuropathy. Monitor ECG if initiated in patients w/ CHF, bradyarrhythmias or concomitant treatment w/ drugs known to prolong QT interval eg, class Ia & III antiarrhythmics, & electrolyte abnormalities. Correct hypokalaemia, hypocalcaemia or hypomagnesaemia prior to treatment. Monitor electrolytes periodically during therapy. Avoid in patients w/ congenital long QT syndrome. Renal & severe hepatic impairment. Minor or moderate influence on the ability to drive or use machines. Women of childbearing potential or males receiving treatment should use effective contraception during & up to 3 mth after treatment. Possibility of irreversible infertility in males. Pregnancy. Childn <18 yr.

Neutropenia, leukopenia, anaemia; decreased appetite; peripheral neuropathy, headache; dyspnoea, cough; nausea, constipation, diarrhoea, vomiting; alopecia; arthralgia, myalgia, back pain, pain in extremity; fatigue, asthenia, pyrexia; decreased wt. UTI, pneumonia, oral candidiasis & herpes, URTI, nasopharyngitis, rhinitis, herpes zoster; lymphopenia, febrile neutropenia, thrombocytopenia; hypokalaemia, hypomagnesaemia, dehydration, hyperglycemia, hypophosphataemia, hypocalcaemia; insomnia, depression; dysgeusia, dizziness, hypoaesthesia, lethargy, neurotoxicity; increased lacrimation, conjunctivitis; vertigo, tinnitus; tachycardia; hot flush, pulmonary embolism; oropharyngeal pain, epistaxis, rhinorrhoea; abdominal pain, stomatitis, dry mouth, dyspepsia, GERD, abdominal distention; increased AST, ALT & γ-glutamyl transferase, hyperbilirubinaemia; rash, pruritus, nail disorder, night sweats, dry skin, erythema, hyperhidrosis, palmar-plantar erythrodysaesthesia; bone pain, muscle spasms, musculoskeletal pain & chest pain, muscular weakness; dysuria; mucosal inflammation, peripheral oedema, pain, chills, chest pain, flu-like illness.

Drugs w/ narrow therapeutic window & eliminated via CYP3A4-mediated metabolism eg, alfentanil, cyclosporine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus.

Cytotoxic Chemotherapy

L01XX41 - eribulin ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.

S